address multiple defects in type 2 diabetes with a convenient once-daily medication1,2
INVOKAMET® XR combines the mechanism of action of INVOKANA® (canagliflozin) with metformin, using a similar technology to Glumetza®1,3,4*
INVOKANA® removes glucose by decreasing the renal reabsorption of filtered glucose, increasing urinary glucose excretion
Metformin decreases hepatic glucose production
Metformin decreases intestinal glucose absorption, and INVOKANA® 300 mg† reduced postprandial glucose excursion due to delayed glucose absorption
Metformin improves insulin sensitivity by increasing peripheral glucose uptake and utilization
*The metformin XR layer of all INVOKAMET® XR doses contains Acuform® technology—the same XR delivery system as Glumetza® 500 mg.
†In single-dose pharmacokinetic/pharmacodynamic studies in healthy people and in patients with type 2 diabetes.
Indicated trademarks are registered trademarks of their respective owners.
References: 1. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Depomed licenses Glumetza® data and Acuform® technology [press release]. Newark, CA: Depomed, Inc.; August 5, 2010. 4. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.